NiKang Therapeutics is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs.
Total raised: $200M
Investors 9
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.05.2021 | Series C | $200M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 10.06.2021 | Wilmington’s NiKang Therapeutics closed a $200M Series C | Biotech is to Delaware’s future as chemical engineering was to its past. When we talk about tech sta... | technical.... |
| 31.05.2021 | NiKang Therapeutics Raises $200M in Series C Financing | NiKang Therapeutics Inc., a Wilmington, Del.-based clinical stage biotech company focused on develop... | finsmes.co... |
| 26.05.2021 | NiKang Therapeutics Announces Completion of $200 Million Ser... | NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovati... | marketscre... |
| - | NiKang Therapeutics Announces Completion of $200 Million Ser... | May 26, 2021 08:00 AM Eastern Daylight Time WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics ... | cbridgecap... |